Johnson & Johnson (NYSE:JNJ) Shares Sold by Moody Lynn & Lieberson LLC

Moody Lynn & Lieberson LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 126,103 shares of the company’s stock after selling 3,814 shares during the period. Johnson & Johnson comprises 1.5% of Moody Lynn & Lieberson LLC’s portfolio, making the stock its 24th largest holding. Moody Lynn & Lieberson LLC’s holdings in Johnson & Johnson were worth $19,765,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Moneta Group Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares in the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $4,609,399,000. Morgan Stanley grew its holdings in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares in the last quarter. Barclays PLC grew its holdings in shares of Johnson & Johnson by 61.0% during the second quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock worth $1,868,351,000 after buying an additional 4,278,512 shares in the last quarter. Finally, Imprint Wealth LLC grew its holdings in shares of Johnson & Johnson by 17,087.7% during the second quarter. Imprint Wealth LLC now owns 2,913,480 shares of the company’s stock worth $291,348,000 after buying an additional 2,896,529 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 28th. Raymond James boosted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, Morgan Stanley lowered their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Johnson & Johnson Price Performance

JNJ opened at $152.31 on Wednesday. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The company has a 50 day moving average of $157.79 and a two-hundred day moving average of $156.18. The company has a market cap of $367.03 billion, a P/E ratio of 11.03, a P/E/G ratio of 2.56 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same period in the previous year, the firm earned $2.35 earnings per share. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.